Evidence map›Paper›PMID 41632423›Full record

ArticleInternational journal of hematology2026

Bronchiolitis obliterans complicating follicular lymphoma: a case series and clinical insights.

Takashi Nakamura, Kazuhito Suzuki, Masaharu Kawashima, Takeshi Saito, Hiroki Yokoyama, Atsushi Katsube, Ryoko Fukushima, Hiroto Ishii, Sayaka Oshima, Susumu Tanoue and 6 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takashi NakamuraDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan. h24ms-nakamura@jikei.ac.jp.
Kazuhito SuzukiDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Masaharu KawashimaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Takeshi SaitoDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Hiroki YokoyamaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Atsushi KatsubeDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Ryoko FukushimaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Hiroto IshiiDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Sayaka OshimaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Susumu TanoueDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Yo SakayoriDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Iku KamitaniDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Keitaro OkudaDepartment of Respiratory Disease, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Takanori NumataDepartment of Respiratory Disease, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Jun ArayaDepartment of Respiratory Disease, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.
Shingo YanoDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-19-18, Nishishinbashi, Minatoku, Tokyo city, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated bronchiolitis obliterans (BO) is a major cause of death and is frequently complicated by paraneoplastic pemphigoid (PNP). In this study, three cases of follicular lymphoma (FL) with BO were retrospectively analyzed. All cases were complicated by PNP. All patients achieved a tumor response with anti-CD20 monoclonal antibody-containing treatment, and two patients showed clinical improvement in PNP. However, BO continued to progress, and two of the three patients developed pulmonary infections.

Indexed as

Bronchiolitis ObliteransLymphoma, FollicularHumansParaneoplastic SyndromesRetrospective StudiesRituximabRituximabAnti-CD20 monoclonal antibodyBronchiolitis obliteransFollicular lymphomaParaneoplastic pemphigoidRespiratory failure

Identifiers

PMID41632423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.